Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Seminars in Oncology|February 1, 2012
p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignanciesYogen Saunthararajah, Pierre Triozzi, Brian Rini, et al.
British Journal of Haematology|August 31, 2019
A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapyFevzi F Yalniz, Jesus G Berdeja, Michael B Maris, et al.
Cancer|September 3, 2011
A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndromeAzra Raza, Naomi Galili, Scott E Smith, et al.
Ebiomedicine|May 26, 2022
Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5qVera Adema, Laura Palomo, Wencke Walter, et al.
The Journal of Clinical Investigation|January 27, 2015
Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromesYogen Saunthararajah, Mikkael Sekeres, Anjali Advani, et al.
American Journal of Hematology|July 28, 2018
Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-RChristopher B Benton, Maliha Khan, David Sallman, et al.
Transfusion|November 24, 2016
Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United StatesAlexander B Pine, Eun-Ju Lee, Mikkael Sekeres, et al.
Blood Advances|August 16, 2022
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndromeCourtney D DiNardo, Sangeetha Venugopal, Curtis Lachowiez, et al.
Blood|June 29, 2012
Revised international prognostic scoring system for myelodysplastic syndromesPeter L Greenberg, Heinz Tuechler, Julie Schanz, et al.
Leukemia|April 30, 2026
How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?Maria Julia Montoro, Pamela Acha, Claudia Haferlach, et al.
Pageof 3